The Inter-American Society of Hypertension (IASH) is a non-profit organization devoted to the understanding, prevention, and control of hypertension and vascular diseases with emphasis on bridging basic, translational, and clinical research across the Americas.
Membership is extended to scientists, physicians, and health care providers from 20 different countries in the Americas, Europe, Australia, and Asia. Anyone interested in the field of hypertension, cardiometabolic risk factors, and cardiovascular diseases is welcome to join the society.
Sign up to receive our newsletter:
COUNCIL ON HYPERTENSION MEETING AND ANNOUNCEMENT OF NEW TRAVEL AWARDS
The IASH granted 10 new investigators from South America with travel awards to attend this year’s American Heart Association Council on Hypertension Scientific Sessions (September 14-17, 2016 – Orlando, FL, USA). The following graduate students and postdoctoral fellows presented their top scored abstracts in either oral or poster presentation format:
- Tiago Fernandes (Department of Biodynamics of Human Movement, School of Physical Education and Sport – University of Sao Paulo, Sao Paulo, Brazil)
- Janaina Ferreira (Heart Institute, School of Medicine – University of Sao Paulo, Sao Paulo, Brazil)
- Sabrina Gonsalez (Carlos Chagas Filho Institute of Biophysics, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil)
- Zaira Palomino Jara (Department of Medicine, Federal University of Sao Paulo, Sao Paulo, Brazil)
- Fernanda Marins (Department of Physiology and Biophysics, Federal University of Minas Gerais, Belo Horizonte, Brazil)
- Alexandre Goes Martini (Department of Molecular Pharmacology, University of Brasilia, Brasilia, Brazil)
- Daisy Motta-Santos (Deptartment of Physiology and Biophysics, Federal University of Minas Gerais, Belo Horizonte, Brazil)
- Ludmila Peres Diaz (Alfredo Lanari Institute of Medical Research, University of Buenos Aires, Buenos Aires, Argentina)
- Alejandro Prado (Department of Pharmacology, School of Medicine of Ribeiro Preto – University of Sao Paulo, Ribeirao Preto, Brazil)
- Katia Scapini (Heart Institute, School of Medicine – University of Sao Paulo, Sao Paulo, Brazil)
The IASH was very pleased to support the career advancement of these young talented investigators! Visit our photo album on Facebook (https://www.facebook.com/IASHonline) to check more pictures of the IASH activities during this scientific meeting.
THE SPRINT TRIAL: A RANDOMIZED TRIAL OF INTENSIVE VERSUS STANDARD BLOOD PRESSURE CONTROL
November 26, 2015
The SPRINT trial compared less-tight control with tight control of hypertension in patients with increased cardiovascular risk but without diabetes. The study included 4678 patients assigned to the intensive treatment of systolic blood pressure (target, <120 mm Hg) and 4683 patients assigned to standard treatment (target, <140 mm Hg). The authors concluded that among patients at high risk for cardiovascular events but without diabetes, targeting a systolic blood pressure of less than 120 mm Hg, as compared with less than 140 mm Hg, resulted in lower rates of fatal and nonfatal major cardiovascular events and death from any cause, although significantly higher rates of some adverse events were observed in the intensive-treatment group (NEJM, November 26, 2015).
DUAL RENIN ANGIOTENSIN SYSTEM BLOCKADE
July 10, 2015
Two studies evaluated the effect of lisinopril combined with telmisartan in early and late stage polycystic kidney disease. In late-stage polycystic kidney disease the rates of decline in the estimated GFR, urinary albumin excretion, and adverse events, including hyperkalemia and acute kidney injury, did not also differ significantly between two groups. Similar conclusions were derived from another published study in which lisinopril and telmisartan were employed in early stage of autosomal dominant polycystic kidney disease.
(Torres VE, Abebe KZ, Chapman AB, Schrier RW, Braun WE, Steinman TI, Winklhofer FT, Brosnahan G, Czarnecki PG, Hogan MC, Miskulin DC, Rahbari-Oskoui FF, Grantham JJ, Harris PC, Flessner MF, Moore CG, Perrone RD; the HALT-PKD Trial Investigators. Angiotensin Blockade in Late Autosomal Dominant Polycystic Kidney Disease. N Engl J Med. 2014 Dec 11;371(24):2267-2276;
Schrier RW, Abebe KZ, Perrone RD, Torres VE, Braun WE, Steinman TI, Winklhofer FT, Brosnahan G, Czarnecki PG, Hogan MC, Miskulin DC, Rahbari-Oskoui FF, Grantham JJ, Harris PC, Flessner MF, Bae KT, Moore CG, Chapman AB; the HALT-PKD Trial Investigators. Blood Pressure in Early Autosomal Dominant Polycystic Kidney Disease. N Engl J Med. 2014 Dec 11;371(24):2255-2266)